Abstract
TheMYCNoncogene is the major negative prognostic marker in neuroblastoma with important roles in both the pathogenesis and clinical behavior of this aggressive malignancy.MYConcogenes activate both proliferative and apoptotic cellular pathways and, accordingly, inhibition of p53-mediated apoptosis is a prerequisite for MYC-driven tumorigenesis. To identify novel transcriptional targets mediating the MYCN-dependent phenotype, we screened a MYCN-amplified neuroblastoma cell line by using chromatin immunoprecipitation (ChIP) cloning. We identified the essential p53 inhibitor and protooncogeneMDM2as a putative target. MDM2 has multiple p53-independent functions modulating cell cycle and transcriptional events. Standard ChIP with MYCN antibodies established the binding of MYCN to a consensus E-box within the humanMDM2promoter. Oligonucleotide pull-down assays further established the capacity of MYCN to bind to this promoter region, confirming the ChIP results. Luciferase reporter assays confirmed the E-box-specific, MYCN-dependent regulation of theMDM2promoter in MYCN-inducible neuroblastoma cell lines. Real-time quantitative PCR and Western blot analysis demonstrated a rapid increase in endogenousMDM2mRNA and MDM2 protein upon induction of MYCN. Targeted inhibition of MYCN in aMYCN-amplified neuroblastoma cell line resulted in decreased MDM2 expression levels with concomitant stabilization of p53 and induction of apoptosis. Our finding that MYCN directly modulates baseline MDM2 levels suggests a mechanism contributing to the pathogenesis of neuroblastoma and other MYC-driven malignancies through inhibition of MYC-stimulated apoptosis.
References
48
Referenced
188
10.1056/NEJM199910143411601
10.1016/S0304-3835(03)00454-3
10.1093/emboj/16.11.2985
- Schweigerer, L., Breit, S., Wenzel, A., Tsunamoto, K., Ludwig, R. & Schwab, M. (1990) Cancer Res. 50, 4411-4416.2364393 / Cancer Res. (1990)
- Lutz, W., Stohr, M., Schurmann, J., Wenzel, A., Lohr, A. & Schwab, M. (1996) Oncogene 13, 803-812.8761302 / Oncogene (1996)
10.1146/annurev.cellbio.16.1.653
10.1038/sj.onc.1202725
10.1038/sj.onc.1202746
10.1073/pnas.96.7.3940
10.1016/S0304-3835(03)00103-4
10.1046/j.1432-1327.1999.00575.x
10.1016/0006-291X(91)91735-U
10.1016/j.gene.2003.09.042
10.1038/sj.onc.1207261
10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9
- Vogan, K., Bernstein, M., Leclerc, J. M., Brisson, L., Brossard, J., Brodeur, G. M., Pelletier, J. & Gros, P. (1993) Cancer Res. 53, 5269-5273.8221661 / Cancer Res. (1993)
- Tonelli R. Fronza R. Purgato S. Camerin C. Bolgna F. Alboresi S. Franzoni M. Corradini R. Sforza S. Faccini A. et al . (2004) Mol. Cancer Ther. in press.
10.1074/jbc.M300771200
10.1016/S1046-2023(02)00007-5
10.1016/S1046-2023(02)00006-3
10.1128/MCB.22.3.856-865.2002
10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y
10.1093/nar/23.14.2584
10.1038/sj.onc.1202949
- Phelps, M., Darley, M., Primrose, J. N. & Blaydes, J. P. (2003) Cancer Res. 63, 2616-2623.12750288 / Cancer Res. (2003)
- Pession, A., Tonelli, R., Fronza, R., Sciamanna, E., Corradini, R., Sforza, S., Tedeschi, T., Marchelli, R., Montanaro, L., Camerin, C., et al. (2004) Int. J. Oncol. 24, 265-272.14719101 / Int. J. Oncol. (2004)
- Nielsen, P. E., Pellestor, F., Paulasova, P. & Koppelhus, U. (2005) Methods Mol. Biol. 288, 343-358.15333914 / Methods Mol. Biol. (2005)
10.1038/sj.ejhg.5201226
10.1016/S0378-1119(99)00487-4
- Moll, U. M. & Petrenko, O. (2003) Mol. Cancer Res. 1, 1001-1008.14707283 / Mol. Cancer Res. (2003)
10.1074/jbc.M312264200
- Ganguli, G. & Wasylyk, B. (2003) Mol. Cancer Res. 1, 1027-1035.14707286 / Mol. Cancer Res. (2003)
- Deb, S. P. (2003) Mol. Cancer Res. 1, 1009-1016.14707284 / Mol. Cancer Res. (2003)
- Meek, D. W. & Knippschild, U. (2003) Mol. Cancer Res. 1, 1017-1026.14707285 / Mol. Cancer Res. (2003)
-
Onel, K. & Cordon-Cardo, C. (2004) Mol. Cancer Res. 2, 1-8.14757840
(
10.1158/1541-7786.1.2.1
) / Mol. Cancer Res. (2004) 10.1038/sj.onc.1206985
10.1128/MCB.21.22.7653-7662.2001
10.1128/MCB.22.5.1360-1368.2002
10.1093/emboj/cdg133
10.1101/gad.1067003
10.1073/pnas.83.6.1772
- Zimmerman, K. & Alt, F. W. (1990) Crit. Rev. Oncog. 2, 75-95.2091750 / Crit. Rev. Oncog. (1990)
10.1038/318533a0
10.1101/gad.13.20.2658
- Knudson, C. M., Johnson, G. M., Lin, Y. & Korsmeyer, S. J. (2001) Cancer Res. 61, 659-665.11212265 / Cancer Res. (2001)
10.1128/MCB.21.15.5063-5070.2001
10.1073/pnas.0401083101
10.1126/science.1092472
Dates
Type | When |
---|---|
Created | 20 years, 7 months ago (Jan. 11, 2005, 10:13 p.m.) |
Deposited | 2 years, 3 months ago (May 1, 2023, 9:53 a.m.) |
Indexed | 1 month ago (July 16, 2025, 8:48 a.m.) |
Issued | 20 years, 7 months ago (Jan. 11, 2005) |
Published | 20 years, 7 months ago (Jan. 11, 2005) |
Published Online | 20 years, 7 months ago (Jan. 11, 2005) |
Published Print | 20 years, 7 months ago (Jan. 18, 2005) |
@article{Slack_2005, title={The p53 regulatory geneMDM2is a direct transcriptional target of MYCN in neuroblastoma}, volume={102}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.0405495102}, DOI={10.1073/pnas.0405495102}, number={3}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Slack, Andrew and Chen, Zaowen and Tonelli, Roberto and Pule, Martin and Hunt, Lisa and Pession, Andrea and Shohet, Jason M.}, year={2005}, month=jan, pages={731–736} }